Dr. Anup K. Kasi Loknath Kumar
Claim this profileUniversity of Kansas Cancer Center
Studies Adenocarcinoma
Studies Cancer
10 reported clinical trials
26 drugs studied
Area of expertise
1Adenocarcinoma
Stage IV
Stage III
BRAF negative
2Cancer
Stage IV
Stage III
BRAF negative
Affiliated Hospitals
Clinical Trials Anup K. Kasi Loknath Kumar is currently running
Olaparib
for Pancreatic Cancer
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.
Recruiting0 awards Phase 232 criteria
Peposertib + Radiation Therapy
for Pancreatic Cancer
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally advanced). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving M3814 and hypofractionated radiation therapy together may be safe, tolerable and more effective than radiation therapy alone in treating patients with locally advanced pancreatic cancer.
Recruiting0 awards Phase 1 & 23 criteria
More about Anup K. Kasi Loknath Kumar
Clinical Trial Related4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Anup K. Kasi Loknath Kumar has experience with
- Fluorouracil
- Capecitabine
- Leucovorin Calcium
- Irinotecan Hydrochloride
- Nivolumab
- Ipilimumab
Breakdown of trials Anup K. Kasi Loknath Kumar has run
Adenocarcinoma
Cancer
Colorectal Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anup K. Kasi Loknath Kumar specialize in?
Anup K. Kasi Loknath Kumar focuses on Adenocarcinoma and Cancer. In particular, much of their work with Adenocarcinoma has involved Stage IV patients, or patients who are Stage III.
Is Anup K. Kasi Loknath Kumar currently recruiting for clinical trials?
Yes, Anup K. Kasi Loknath Kumar is currently recruiting for 4 clinical trials in Kansas City Kansas. If you're interested in participating, you should apply.
Are there any treatments that Anup K. Kasi Loknath Kumar has studied deeply?
Yes, Anup K. Kasi Loknath Kumar has studied treatments such as Fluorouracil, Capecitabine, Leucovorin Calcium.
What is the best way to schedule an appointment with Anup K. Kasi Loknath Kumar?
Apply for one of the trials that Anup K. Kasi Loknath Kumar is conducting.
What is the office address of Anup K. Kasi Loknath Kumar?
The office of Anup K. Kasi Loknath Kumar is located at: University of Kansas Cancer Center, Kansas City, Kansas 66160 United States. This is the address for their practice at the University of Kansas Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.